文献速递神经肿瘤

CCDC34在低级别胶质瘤中的致癌作用:预后意义与治疗潜力

The oncogenic role of CCDC34 in lower-grade gliomas: prognostic significance and therapeutic potential.
PubMed 文献 · J Neurooncol · 2025-06-16

该研究基于TCGA、CGGA和GEO数据库共1064例低级别胶质瘤样本,分析CCDC34表达与临床结局的相关性。结果显示CCDC34高表达与高级别、复发和不良总生存显著相关,被证实为独立预后风险因素,并通过DNA甲基化和PI3K-Akt、HIF-1、Notch等通路参与恶性进展。

要点

  • CCDC34高表达与低级别胶质瘤高级别、复发及不良总生存显著相关。
  • cg19157696高甲基化负调控CCDC34表达,与更好患者结局相关。
  • 沉默CCDC34可显著降低低级别胶质瘤细胞增殖、迁移和体内成瘤。

核心结论

  • CCDC34在低级别胶质瘤中发挥致癌基因作用,与不良预后和恶性进展密切相关。
  • CCDC34受DNA甲基化调控并参与关键致癌通路,有潜力作为预后生物标志物和治疗靶点。

研究设计与样本

  • 研究整合TCGA、CGGA和GEO数据库共1064例低级别胶质瘤患者样本进行回顾性分析。
  • 采用Kaplan-Meier分析、Cox回归、PPI、虚拟筛选和meta分析评估预后意义。
  • 机制研究包括DNA甲基化分析和KEGG通路富集,并通过体外和体内实验验证功能。

主要发现

  • CCDC34表达升高与高级别肿瘤、复发和不良总生存显著相关。
  • Meta分析确认CCDC34为预后的独立风险因素。
  • cg19157696甲基化负调控CCDC34表达,高甲基化与更好患者结局相关。
  • CCDC34参与PI3K-Akt、HIF-1和Notch等致癌通路,促进肿瘤细胞增殖、侵袭和免疫微环境调节。
  • 发现五类小分子药物可能具有抑制CCDC34表达的潜力。

临床怎么用

  • CCDC34表达水平或可作为低级别胶质瘤预后评估的候选生物标志物。
  • 靶向CCDC34及其相关通路可能为低级别胶质瘤提供潜在治疗策略。
  • cg19157696甲基化状态可能辅助判断患者预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the prognostic significance, molecular mechanisms, and therapeutic potential of CCDC34 in lower-grade gliomas (LGG). METHODS: Data from TCGA, CGGA, and GEO databases, comprising 1,064 LGG patient samples, were analyzed to evaluate the correlation between CCDC34 expression and clinical outcomes. Kaplan-Meier analysis, Cox regression, PPI, Virtual screening and meta-analysis were conducted to assess its prognostic significance. Mechanistic studies included DNA methylation analysis and KEGG pathway enrichment to explore regulatory mechanisms. In vitro and in vivo experiments were performed to validate its effects on tumor cell proliferation, migration, and tumorigenesis. RESULTS: Elevated CCDC34 expression was significantly associated with advanced tumor grade, recurrence, and poor overall survival. Meta-analysis confirmed CCDC34 as an independent risk factor for prognosis. DNA methylation analysis revealed that CCDC34 expression is negatively regulated by cg19157696 methylation, with hypermethylation correlating with better patient outcomes. Pathway enrichment analyses showed that CCDC34 is involved in critical oncogenic pathways, including PI3K-Akt, HIF-1, and Notch, which promote tumor cell proliferation, invasion, and immune microenvironment modulation. It has also been found that five types of small-molecule drugs may have the potential to inhibit the expression of CCDC34. Functional validation demonstrated that silencing CCDC34 significantly reduced LGG cell proliferation, migration, and tumor formation in vitro and in vivo. CONCLUSIONS: CCDC34 acts as an oncogene in LGG and is strongly associated with poor prognosis and malignant progression. Its regulation via DNA methylation and involvement in key pathways highlight its potential as a prognostic biomarker and therapeutic target.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Shen H, Li J, Jia Y, et al. The oncogenic role of CCDC34 in lower-grade gliomas: prognostic significance and therapeutic potential. J Neurooncol. 2025. PMID: 40522566. doi:10.1007/s11060-025-05090-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。